Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
33643-46-8
Molecular formula
C13H16ClNO
Molecular weight
237.72 g/mol
Drug class
S-enantiomer of ketaminenon-selective, non-competitive NMDA receptor antagonist
Mechanism of action
Non-competitively antagonises NMDA glutamate receptors. Its antidepressant effects may involve downstream changes in synaptic plasticity and glutamatergic signalling; the precise mechanism underlying clinical response is not fully established.
Indications / reported uses
Treatment-resistant depression in adults, in conjunction with an oral antidepressant under the US product indication
Depressive symptoms in adults with major depressive disorder and acute suicidal ideation or behaviour, in conjunction with standard care; the label does not establish prevention of suicide or reduction of suicidal behaviour
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Esketamine Environmental Risk Assessment (ERA) (the Esketamine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.